Correction: Real time  ex vivo  chemosensitivity assay for pancreatic adenocarcinoma

Dae Won Kim; Francisca Beato; Youngchul Kim; Alexandra F. Tassielli; Ruifan Dai; Jason W. Denbo; Pamela J. Hodul; Mokenge P. Malafa; Jason B. Fleming

doi:10.18632/oncotarget.28556

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma

PDF | How to cite

Oncotarget. 2024; 15:441-441. https://doi.org/10.18632/oncotarget.28556

Metrics: PDF 489 views | ?

Dae Won Kim^1,*, Francisca Beato^1,*, Youngchul Kim², Alexandra F. Tassielli¹, Ruifan Dai¹, Jason W. Denbo¹, Pamela J. Hodul¹, Mokenge P. Malafa¹ and Jason B. Fleming¹

¹Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
²Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA
^*These authors contributed equally to this work

Published: July 02, 2024

Copyright: © 2024 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The following author has been added to this paper.

Bhaswati Sarcar
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA

Original article: Oncotarget. 2023; 14:811–818. DOI: https://doi.org/10.18632/oncotarget.28508

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28556

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma